On November 11, Luye Pharma announced on the Hong Kong Stock Exchange that the Group's Class 1 innovative drug LY03021 has been approved by the China National Medical Products Administration Center for Drug Evaluation to conduct clinical trials for the treatment of depression.
绿叶制药：1类创新药LY03021获准开展临床试验，拟用于治疗抑郁症
Luye Pharma: Class 1 innovative drug LY03021 approved for clinical trials, intended for the treatment of depression.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated